The FDA updated its database of drugs in shortage to remove tirzepatide, which had sat on that list – along with related ...
Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...
There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.
On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 ...
A recently released negative study by Novo Nordisk (NVO) on the differences between its own semaglutide and liraglutide ...
WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
The FDA has issued warnings about the risks of compounded semaglutide. Ren-Fielding and her team often ask visiting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback